


5

What is claimed is

1. A process for preparing an optically active 5-hydroxy-3-ketoester of the formula **A1** or **A2**



10

A1 or **A2**

or one of the tautomers thereof,


wherein R^1 and R^2 independently of each other represent hydrogen or a group which is selected from among C_1 - C_8 -alkyl, C_3 - C_8 -cycloalkyl, C_6 - C_{10} -aryl and C_1 - C_8 -alkylene- C_6 - C_{10} -aryl, optionally with one, two or three substituents, selected from among hydroxy, halogen, C_1 - C_4 -alkoxy and CF_3 , where R^1 and R^2 do not simultaneously have the same meaning, and

15

R^3 denotes a group selected from among C_1 - C_8 -alkyl, C_1 - C_4 -Haloalkyl, C_6 - C_{10} -aryl- C_1 - C_8 -alkylene and trihydrocarbylsilyl, characterised in that a

20

racemic mixture of a 5-hydroxy-3-ketoester of formula **A**



A

wherein R^1 , R^2 and R^3 are as hereinbefore defined,

25

is resolved into the two enantiomeric 5-hydroxy-3-ketoester **A1** and **A2** by preparative high performance liquid chromatography (HPLC) over a chiral carrier material.

5 **2.** The process according to claim 1, wherein the two separate enantiomeric 5-hydroxy-3-ketoesters **A1** and **A2** are each obtained in an enantiomer excess of at least 95%.

10 **3.** The process according to claim 1, wherein R^1 and R^2 independently of each other are selected from the group consisting of methyl, ethyl, propyl, butyl, phenyl, benzyl, phenylethyl and phenylpropyl, optionally with a substituent selected from the group consisting of hydroxy, fluorine, chlorine, bromine, methoxy, ethoxy and CF_3 .

15 **4.** The process according to claim 1, wherein R^3 is selected from the group consisting of methyl, ethyl, propyl, butyl and benzyl.

20 **5.** The process according to claim 1, wherein R^1 denotes 2-phenylethyl and R^2 denote propyl or R^1 denotes propyl and R^2 denotes 2-phenylethyl.

25 **6.** The process according to claim 1, wherein R^3 denotes tert.-butyl or ethyl.

30 **7.** The process according to claim 5, wherein R^1 denotes 2-phenylethyl, R^2 denotes propyl and R^3 denotes ethyl or tert.-butyl.

35 **8.** The process according to claim 1, wherein chemically modified polysaccharide is used as the chiral carrier material.

40 **9.** The process according to claim 8, wherein the chemically modified polysaccharide is a polysaccharide which contains one or more optically active groups chemically bound.

45 **10.** The process according to claim 8, wherein the polysaccharide is selected from the group consisting of dextrin, cyclodextrin, starch, amylose and cellulose.

5 **11.** The process according to claim 8, wherein the carrier material is selected from the group consisting of tris(3,5-dimethylphenylcarbamate)-amylose, tris[(S)- α -methylbenzylcarbamate]-amylose, tris(3,5-dimethylphenylcarbamate)-cellulose, tris(4-methylbenzoate)-cellulose, cellulose triacetate, cellulose tribenzoate, tris(phenylcarbamate)-cellulose, tris(4-chlorophenylcarbamate)-cellulose,
10 cellulose tricinnamate and cellulose tribenzoate.

15 **12.** The process according to claim 8, wherein tris(3,5-dimethylphenylcarbamate)-amylose or tris(3,5-dimethylphenylcarbamate)-cellulose is used as the carrier material.


13. The process according to claim 1, wherein the preparative HPLC is used in the form of SMB (Simulated Moving Bed) chromatography.

14. A method for preparing an optically active dihydropyrone of formula **B**



or one of the tautomers thereof,

wherein R^1 and R^2 independently of each another denote hydrogen or a group selected from among C_1 - C_8 -alkyl, C_3 - C_8 -cycloalkyl, C_6 - C_{10} -aryl and C_1 - C_8 -alkylene- C_6 - C_{10} -aryl, optionally with one, two or three substituents, selected from
25 among hydroxy, halogen, C_1 - C_4 -alkoxy and CF_3 , wherein R^1 and R^2 do not simultaneously have the same meaning, wherein an optically active 5-hydroxy-3-ketoester of formula **A1** or **A2**



5

A1 or A2

is cyclised according to methods known *per se* to form an optically active dihydropyrone of formula B.

10 **15.** The method of claim 14 wherein the dihydropyrone of formula B is tipranavir.